|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02181 MABPHARM-B
Nominal 
0.600 0.000 (0.000%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 258,228 | 196.266% | 87,161 | 55,918 | 82,882 | 0 |
| Cost of Sales | (38,834) | 225.707% | (11,923) | (15,375) | (16,777) | -- |
| Gross Profit | 219,394 | 191.600% | 75,238 | 40,543 | 66,105 | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (1,879) | 340.047% | (427) | (118) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (127,947) | -38.885% | (209,356) | (210,819) | (291,744) | (184,632) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (127,947) | -38.885% | (209,356) | (210,819) | (291,744) | (184,632) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 10,039 | 6.492% | 9,427 | 6,806 | 449 | (5,516) |
| Depreciation & Amortisation | 61,329 | 1.045% | 60,695 | 51,549 | 43,877 | 24,397 |
| Directors' Emoluments | 15,497 | 35.380% | 11,447 | 7,878 | 10,309 | 12,913 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -3.000 | -40.000% | -5.000 | -5.000 | -7.000 | -4.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.001) | -- | 0.014 | (0.014) | (0.048) | (0.036) |
| NBV per share ($) | 0.022 | -- | 0.050 | 0.097 | 0.146 | 0.214 |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,898 |
| %Change | -- |
| EPS / (LPS) | RMB 0.001 |
| NBV Per Share (¥) | RMB 0.024 |